{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:48:40Z","timestamp":1789084120550,"version":"build-2803163510"},"reference-count":302,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03981-3","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T19:24:47Z","timestamp":1764012287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeted drug conjugates and molecular mechanisms in overcoming lung cancer drug resistance"],"prefix":"10.1007","volume":"16","author":[{"given":"Lu","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rou","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"21","key":"3981_CR1","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"issue":"1","key":"3981_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","volume":"23","author":"M Araghi","year":"2023","unstructured":"Araghi M, et al. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int. 2023;23(1):162.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"3981_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.lungcan.2013.07.025","volume":"82","author":"LA Pikor","year":"2013","unstructured":"Pikor LA, et al. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013;82(2):179\u201389.","journal-title":"Lung Cancer"},{"key":"3981_CR4","doi-asserted-by":"crossref","unstructured":"Krpina K et al. Small cell lung carcinoma: current diagnosis, biomarkers, and treatment options with future perspectives. Biomedicines. 2023:13;11(7):1982.","DOI":"10.3390\/biomedicines11071982"},{"issue":"10445","key":"3981_CR5","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1016\/S0140-6736(24)01299-6","volume":"403","author":"L The","year":"2024","unstructured":"The L. Lung cancer treatment: 20 years of progress. Lancet. 2024;403(10445):2663.","journal-title":"Lancet"},{"issue":"39","key":"3981_CR6","doi-asserted-by":"publisher","first-page":"32512","DOI":"10.1074\/jbc.M112.351957","volume":"287","author":"CY Wang","year":"2012","unstructured":"Wang CY, et al. Annexin A2 Silencing induces G2 arrest of non-small cell lung cancer cells through p53-dependent and -independent mechanisms. J Biol Chem. 2012;287(39):32512\u201324.","journal-title":"J Biol Chem"},{"issue":"1","key":"3981_CR7","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023;8(1):262.","journal-title":"Signal Transduct Target Ther"},{"issue":"21","key":"3981_CR8","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMe2311559","volume":"389","author":"YL Wu","year":"2023","unstructured":"Wu YL, Zhou Q. Combination therapy for EGFR-Mutated lung cancer. N Engl J Med. 2023;389(21):2005\u20137.","journal-title":"N Engl J Med"},{"issue":"8","key":"3981_CR9","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1200\/JCO.2012.44.5353","volume":"31","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31(8):1105\u201311.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3981_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","volume":"18","author":"A Drilon","year":"2021","unstructured":"Drilon A, et al. ROS1-dependent cancers - biology, diagnostics and therapeutics. Nat Rev Clin Oncol. 2021;18(1):35\u201355.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"3981_CR11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","volume":"32","author":"M Reck","year":"2021","unstructured":"Reck M, et al. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021;32(9):1101\u201310.","journal-title":"Ann Oncol"},{"issue":"22","key":"3981_CR12","doi-asserted-by":"publisher","first-page":"5371","DOI":"10.7150\/jca.35247","volume":"10","author":"H Zhuang","year":"2019","unstructured":"Zhuang H, et al. Increase of secondary mutations May be a drug-resistance mechanism for lung adenocarcinoma after radiation therapy combined with tyrosine kinase inhibitor. J Cancer. 2019;10(22):5371\u20136.","journal-title":"J Cancer"},{"key":"3981_CR13","doi-asserted-by":"publisher","first-page":"175883592211305","DOI":"10.1177\/17588359221130503","volume":"14","author":"Y Sato","year":"2022","unstructured":"Sato Y, Saito G, Fujimoto D. Histologic transformation in lung cancer: when one door shuts, another opens. Ther Adv Med Oncol. 2022;14:17588359221130503.","journal-title":"Ther Adv Med Oncol"},{"key":"3981_CR14","doi-asserted-by":"publisher","first-page":"1447678","DOI":"10.3389\/fonc.2024.1447678","volume":"14","author":"Z Jiang","year":"2024","unstructured":"Jiang Z, et al. Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Front Oncol. 2024;14:1447678.","journal-title":"Front Oncol"},{"key":"3981_CR15","doi-asserted-by":"crossref","unstructured":"Lin A et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med. 2019;11(509):eaaw8412.","DOI":"10.1126\/scitranslmed.aaw8412"},{"issue":"8","key":"3981_CR16","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41571-024-00914-x","volume":"21","author":"T Sen","year":"2024","unstructured":"Sen T, et al. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nat Rev Clin Oncol. 2024;21(8):610\u201327.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"3981_CR17","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.18632\/oncotarget.1891","volume":"5","author":"E Shtivelman","year":"2014","unstructured":"Shtivelman E, et al. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014;5(6):1392.","journal-title":"Oncotarget"},{"issue":"31","key":"3981_CR18","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1038\/sj.onc.1203698","volume":"19","author":"W-L Wang","year":"2000","unstructured":"Wang W-L, et al. Growth Inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000;19(31):3521\u20138.","journal-title":"Oncogene"},{"issue":"3","key":"3981_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/JTO.0b013e3181653d1b","volume":"3","author":"S Ramalingam","year":"2008","unstructured":"Ramalingam S, et al. Dual Inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. J Thorac Oncol. 2008;3(3):258\u201364.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"3981_CR20","doi-asserted-by":"publisher","first-page":"100015","DOI":"10.1016\/j.cellin.2022.100015","volume":"1","author":"Z Wang","year":"2022","unstructured":"Wang Z, et al. Current therapy and development of therapeutic agents for lung cancer. Cell Insight. 2022;1(2):100015.","journal-title":"Cell Insight"},{"issue":"7","key":"3981_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/cancers10070224","volume":"10","author":"Z Schrank","year":"2018","unstructured":"Schrank Z, et al. Current molecular-targeted therapies in NSCLC and their mechanism of resistance. Cancers. 2018;10(7):224.","journal-title":"Cancers"},{"issue":"8","key":"3981_CR22","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S1470-2045(16)30123-1","volume":"17","author":"W-L Tan","year":"2016","unstructured":"Tan W-L, et al. Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol. 2016;17(8):e347\u201362.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3981_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3816\/CLC.2010.n.012","volume":"11","author":"M Provencio","year":"2010","unstructured":"Provencio M, et al. New molecular targeted therapies integrated with radiation therapy in lung cancer. Clin Lung Cancer. 2010;11(2):91\u20137.","journal-title":"Clin Lung Cancer"},{"issue":"12","key":"3981_CR24","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","volume":"3","author":"EA Akbay","year":"2013","unstructured":"Akbay EA, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3(12):1355\u201363.","journal-title":"Cancer Discov"},{"issue":"6","key":"3981_CR25","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.cell.2013.08.015","volume":"154","author":"Y Wei","year":"2013","unstructured":"Wei Y, et al. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell. 2013;154(6):1269\u201384.","journal-title":"Cell"},{"issue":"18","key":"3981_CR26","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","volume":"363","author":"YL Choi","year":"2010","unstructured":"Choi YL, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363(18):1734\u20139.","journal-title":"N Engl J Med"},{"issue":"7","key":"3981_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.18632\/oncotarget.186","volume":"1","author":"Z Zhang","year":"2010","unstructured":"Zhang Z, et al. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget. 2010;1(7):497.","journal-title":"Oncotarget"},{"issue":"12","key":"3981_CR28","doi-asserted-by":"publisher","first-page":"s4227","DOI":"10.1158\/1078-0432.CCR-040007","volume":"10","author":"GV Scagliotti","year":"2004","unstructured":"Scagliotti GV, et al. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res. 2004;10(12):s4227\u201332.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3981_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma SV, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169\u201381.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3981_CR30","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1038\/onc.2009.198","volume":"28","author":"A Gazdar","year":"2009","unstructured":"Gazdar A. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(1):S24\u201331.","journal-title":"Oncogene"},{"issue":"216","key":"3981_CR31","doi-asserted-by":"publisher","first-page":"ra216177","DOI":"10.1126\/scitranslmed.3007205","volume":"5","author":"H Yasuda","year":"2013","unstructured":"Yasuda H, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013;5(216):ra216177\u2013216177.","journal-title":"Sci Transl Med"},{"issue":"12","key":"3981_CR32","doi-asserted-by":"publisher","first-page":"S342","DOI":"10.1097\/JTO.0b013e318271c798","volume":"7","author":"N Somaiah","year":"2012","unstructured":"Somaiah N, Simon NG, Simon GR. A tabulated summary of targeted and biologic therapies for Non\u2013Small-Cell lung cancer. J Thorac Oncol. 2012;7(12):S342\u201368.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"3981_CR33","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","volume":"21","author":"M Fukuoka","year":"2003","unstructured":"Fukuoka M, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non\u2013small-cell lung cancer. J Clin Oncol. 2003;21(12):2237\u201346.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3981_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, et al. Erlotinib in previously treated non\u2013small-cell lung cancer. N Engl J Med. 2005;353(2):123\u201332.","journal-title":"N Engl J Med"},{"issue":"2","key":"3981_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121\u20138.","journal-title":"Lancet Oncol"},{"issue":"3","key":"3981_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239\u201346.","journal-title":"Lancet Oncol"},{"issue":"8","key":"3981_CR37","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735\u201342.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3981_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","volume":"16","author":"JC-H Yang","year":"2015","unstructured":"Yang JC-H, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141\u201351.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3981_CR39","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"Y-L Wu","year":"2017","unstructured":"Wu Y-L, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454\u201366.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3981_CR40","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1097\/JTO.0000000000000647","volume":"10","author":"A Hata","year":"2015","unstructured":"Hata A, et al. Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non\u2013small-cell lung cancer after acquired resistance to EGFR-TKI. J Thorac Oncol. 2015;10(11):1553\u20139.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"3981_CR41","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DA Cross","year":"2014","unstructured":"Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046\u201361.","journal-title":"Cancer Discov"},{"issue":"7","key":"3981_CR42","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, et al. Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer. N Engl J Med. 2017;376(7):629\u201340.","journal-title":"N Engl J Med"},{"issue":"2","key":"3981_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, et al. Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325.","journal-title":"N Engl J Med"},{"issue":"12","key":"3981_CR44","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.jtho.2020.09.001","volume":"15","author":"JC-H Yang","year":"2020","unstructured":"Yang JC-H, et al. Safety, efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: a multicenter, open-label, phase 1 trial. J Thorac Oncol. 2020;15(12):1907\u201318.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"3981_CR45","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jtho.2020.11.028","volume":"16","author":"M Nagasaka","year":"2021","unstructured":"Nagasaka M, et al. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR\u2009+\u2009NSCLC. J Thorac Oncol. 2021;16(5):740\u201363.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"3981_CR46","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1097\/JTO.0b013e318189f50e","volume":"3","author":"H Borghaei","year":"2008","unstructured":"Borghaei H, et al. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol. 2008;3(11):1286\u201392.","journal-title":"J Thorac Oncol"},{"issue":"34","key":"3981_CR47","doi-asserted-by":"publisher","first-page":"8786","DOI":"10.1200\/JCO.2005.03.1997","volume":"23","author":"CD Thienelt","year":"2005","unstructured":"Thienelt CD, et al. Multicenter phase I\/II study of cetuximab with Paclitaxel and carboplatin in untreated patients with stage IV non\u2013small-cell lung cancer. J Clin Oncol. 2005;23(34):8786\u201393.","journal-title":"J Clin Oncol"},{"issue":"18suppl","key":"3981_CR48","doi-asserted-by":"publisher","first-page":"7545","DOI":"10.1200\/jco.2007.25.18_suppl.7545","volume":"25","author":"R Herbst","year":"2007","unstructured":"Herbst R, et al. A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342. J Clin Oncol. 2007;25(18suppl):7545\u20137545.","journal-title":"J Clin Oncol"},{"issue":"18suppl","key":"3981_CR49","doi-asserted-by":"publisher","first-page":"7586","DOI":"10.1200\/jco.2007.25.18_suppl.7586","volume":"25","author":"M Saleh","year":"2007","unstructured":"Saleh M, et al. Randomized phase II trial of two dose schedules of carboplatin\/paclitaxel\/cetuximab in stage IIIB\/IV non-small cell lung cancer (NSCLC). J Clin Oncol. 2007;25(18suppl):7586\u20137586.","journal-title":"J Clin Oncol"},{"issue":"36","key":"3981_CR50","doi-asserted-by":"publisher","first-page":"9089","DOI":"10.1200\/JCO.2004.00.1438","volume":"23","author":"F Robert","year":"2005","unstructured":"Robert F, et al. Phase I\/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non\u2013small-cell lung cancer. J Clin Oncol. 2005;23(36):9089\u201396.","journal-title":"J Clin Oncol"},{"issue":"15suppl","key":"3981_CR51","doi-asserted-by":"publisher","first-page":"19005","DOI":"10.1200\/jco.2008.26.15_suppl.19005","volume":"26","author":"L Pilz","year":"2008","unstructured":"Pilz L, et al. Feasibility of cetuximab in combination with gemcitabine or docetaxel or carboplatin\/gemcitabine for chemona\u00efve patients with advanced non-small cell lung cancer (NSCLC): observations from an ongoing randomized phase II\/III trial (GemTax IV). J Clin Oncol. 2008;26(15suppl):19005\u201319005.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3981_CR52","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1200\/JCO.2009.21.9618","volume":"28","author":"TJ Lynch","year":"2010","unstructured":"Lynch TJ, et al. Cetuximab and first-line taxane\/carboplatin chemotherapy in advanced non\u2013small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010;28(6):911\u20137.","journal-title":"J Clin Oncol"},{"issue":"15suppl","key":"3981_CR53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1200\/jco.2008.26.15_suppl.3","volume":"26","author":"R Pirker","year":"2008","unstructured":"Pirker R, et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin\/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2008;26(15suppl):3\u20133.","journal-title":"J Clin Oncol"},{"key":"3981_CR54","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3389\/fonc.2012.00192","volume":"2","author":"A Wellstein","year":"2012","unstructured":"Wellstein A. ALK receptor activation, ligands and therapeutic targeting in glioblastoma and in other cancers. Front Oncol. 2012;2:192.","journal-title":"Front Oncol"},{"issue":"12","key":"3981_CR55","doi-asserted-by":"publisher","first-page":"9526","DOI":"10.1074\/jbc.M007333200","volume":"276","author":"B Souttou","year":"2001","unstructured":"Souttou B, et al. Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J Biol Chem. 2001;276(12):9526\u201331.","journal-title":"J Biol Chem"},{"key":"3981_CR56","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11523-012-0227-8","volume":"7","author":"AM La Madrid","year":"2012","unstructured":"La Madrid AM, et al. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin\u2019s lymphoma, and neuroblastoma. Target Oncol. 2012;7:199\u2013210.","journal-title":"Target Oncol"},{"issue":"8","key":"3981_CR57","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1158\/1078-0432.CCR-10-1591","volume":"17","author":"AT Shaw","year":"2011","unstructured":"Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res. 2011;17(8):2081\u20136.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3981_CR58","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nm0311-290","volume":"17","author":"A Wellstein","year":"2011","unstructured":"Wellstein A, Toretsky JA. Hunting ALK to feed targeted cancer therapy. Nat Med. 2011;17(3):290\u20131.","journal-title":"Nat Med"},{"issue":"6","key":"3981_CR59","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/cncy.21418","volume":"122","author":"A Proietti","year":"2014","unstructured":"Proietti A, et al. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non\u2013small cell lung cancer: comparison with histological assessment. Cancer Cytopathol. 2014;122(6):445\u201353.","journal-title":"Cancer Cytopathol"},{"issue":"7153","key":"3981_CR60","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, et al. Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561\u20136.","journal-title":"Nature"},{"issue":"26","key":"3981_CR61","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","volume":"27","author":"AT Shaw","year":"2009","unstructured":"Shaw AT, et al. Clinical features and outcome of patients with non\u2013small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247\u201353.","journal-title":"J Clin Oncol"},{"key":"3981_CR62","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1245\/s10434-009-0808-7","volume":"17","author":"T Takahashi","year":"2010","unstructured":"Takahashi T, et al. Clinicopathologic features of non-small-cell lung cancer with EML4\u2013ALK fusion gene. Ann Surg Oncol. 2010;17:889\u201397.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"3981_CR63","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1634\/theoncologist.2014-0241","volume":"19","author":"D Kazandjian","year":"2014","unstructured":"Kazandjian D, et al. FDA approval summary: Crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist. 2014;19(10):e5\u201311.","journal-title":"Oncologist"},{"issue":"25","key":"3981_CR64","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385\u201394.","journal-title":"N Engl J Med"},{"issue":"2","key":"3981_CR65","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cllc.2014.09.011","volume":"16","author":"S Li","year":"2015","unstructured":"Li S, et al. Ceritinib (LDK378): A potent alternative to Crizotinib for ALK-Rearranged Non\u2013Small-Cell lung cancer. Clin Lung Cancer. 2015;16(2):86\u201391.","journal-title":"Clin Lung Cancer"},{"key":"3981_CR66","first-page":"429","volume-title":"ALK inhibitors in non\u2013small cell lung cancer: Crizotinib and beyond","author":"MM Awad","year":"2014","unstructured":"Awad MM, Shaw AT. ALK inhibitors in non\u2013small cell lung cancer: Crizotinib and beyond. Volume 12. Clinical advances in hematology & oncology: H&O; 2014. p. 429. 7."},{"issue":"13","key":"3981_CR67","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","volume":"370","author":"AT Shaw","year":"2014","unstructured":"Shaw AT, et al. Ceritinib in ALK-rearranged non\u2013small-cell lung cancer. N Engl J Med. 2014;370(13):1189\u201397.","journal-title":"N Engl J Med"},{"issue":"23","key":"3981_CR68","doi-asserted-by":"publisher","first-page":"9827","DOI":"10.1158\/0008-5472.CAN-10-1671","volume":"70","author":"Z Chen","year":"2010","unstructured":"Chen Z, et al. Inhibition of ALK, PI3K\/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res. 2010;70(23):9827\u201336.","journal-title":"Cancer Res"},{"issue":"4","key":"3981_CR69","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1158\/2159-8290.CD-12-0440","volume":"3","author":"J Sang","year":"2013","unstructured":"Sang J, et al. Targeted Inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non\u2013small cell lung cancer. Cancer Discov. 2013;3(4):430\u201343.","journal-title":"Cancer Discov"},{"issue":"11","key":"3981_CR70","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1158\/1078-0432.CCR-12-3381","volume":"19","author":"MA Socinski","year":"2013","unstructured":"Socinski MA, et al. A multicenter phase II study of Ganetespib monotherapy in patients with genotypically defined advanced non\u2013small cell lung cancer. Clin Cancer Res. 2013;19(11):3068\u201377.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3981_CR71","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jtho.2017.11.131","volume":"13","author":"E Felip","year":"2018","unstructured":"Felip E, et al. Phase 2 study of the HSP-90 inhibitor AUY922 in previously treated and molecularly defined patients with advanced Non-Small cell lung cancer. J Thorac Oncol. 2018;13(4):576\u201384.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"3981_CR72","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/JTO.0b013e318283dcc0","volume":"8","author":"S Kim","year":"2013","unstructured":"Kim S, et al. Heterogeneity of genetic changes associated with acquired Crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol. 2013;8(4):415\u201322.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"3981_CR73","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","volume":"18","author":"RC Doebele","year":"2012","unstructured":"Doebele RC, et al. Mechanisms of resistance to Crizotinib in patients with ALK gene rearranged non\u2013small cell lung cancer. Clin Cancer Res. 2012;18(5):1472\u201382.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"3981_CR74","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw AT, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590\u20139.","journal-title":"Lancet Oncol"},{"issue":"209","key":"3981_CR75","first-page":"209ra153","volume":"5","author":"TCLCG Project","year":"2013","unstructured":"Project TCLCG, NGM NGM. A genomics-based classification of human lung tumors. Sci Transl Med. 2013;5(209):209ra153.","journal-title":"Sci Transl Med"},{"issue":"1","key":"3981_CR76","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1508887","volume":"374","author":"AT Shaw","year":"2016","unstructured":"Shaw AT, et al. Resensitization to Crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med. 2016;374(1):54\u201361.","journal-title":"N Engl J Med"},{"issue":"4","key":"3981_CR77","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ijc.29825","volume":"138","author":"JS Ross","year":"2016","unstructured":"Ross JS, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer. 2016;138(4):881\u201390.","journal-title":"Int J Cancer"},{"issue":"15","key":"3981_CR78","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1200\/JCO.2010.33.1280","volume":"29","author":"PK Paik","year":"2011","unstructured":"Paik PK, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29(15):2046\u201351.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3981_CR79","first-page":"142","volume":"4","author":"PP Luk","year":"2015","unstructured":"Luk PP, et al. BRAF mutations in non-small cell lung cancer. Translational Lung Cancer Res. 2015;4(2):142.","journal-title":"Translational Lung Cancer Res"},{"key":"3981_CR80","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/annonc\/mdu438.46","volume":"25","author":"D Planchard","year":"2014","unstructured":"Planchard D, et al. Dabrafenib in patients with BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): a multicenter, open-label, phase II trial (BRF113928). Ann Oncol. 2014;25:v1.","journal-title":"Ann Oncol"},{"issue":"5","key":"3981_CR81","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1097\/JTO.0b013e31828bb1b3","volume":"8","author":"CM Rudin","year":"2013","unstructured":"Rudin CM, Hong K, Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor Dabrafenib in a patient with BRAF-mutant non\u2013small-cell lung cancer. J Thorac Oncol. 2013;8(5):e41\u20132.","journal-title":"J Thorac Oncol"},{"issue":"23","key":"3981_CR82","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.1158\/0008-5472.CAN-11-1243","volume":"71","author":"J Villanueva","year":"2011","unstructured":"Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 2011;71(23):7137\u201340.","journal-title":"Cancer Res"},{"issue":"2","key":"3981_CR83","doi-asserted-by":"publisher","first-page":"e0118210","DOI":"10.1371\/journal.pone.0118210","volume":"10","author":"M Joshi","year":"2015","unstructured":"Joshi M, et al. Trametinib with or without Vemurafenib in BRAF mutated non-small cell lung cancer. PLoS ONE. 2015;10(2):e0118210.","journal-title":"PLoS ONE"},{"issue":"8","key":"3981_CR84","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","volume":"30","author":"K Bergethon","year":"2012","unstructured":"Bergethon K, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863\u201370.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3981_CR85","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.hemonc.2020.11.005","volume":"14","author":"JM Araujo","year":"2021","unstructured":"Araujo JM, et al. Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: evidence to date. Hematol Oncol Stem Cell Ther. 2021;14(3):192\u20138.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"21","key":"3981_CR86","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","volume":"371","author":"AT Shaw","year":"2014","unstructured":"Shaw AT, et al. Crizotinib in ROS1-rearranged non\u2013small-cell lung cancer. N Engl J Med. 2014;371(21):1963\u201371.","journal-title":"N Engl J Med"},{"issue":"10","key":"3981_CR87","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","volume":"8","author":"A Drilon","year":"2018","unstructured":"Drilon A, et al. Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent-front mutations. Cancer Discov. 2018;8(10):1227\u201336.","journal-title":"Cancer Discov"},{"issue":"2","key":"3981_CR88","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.critrevonc.2013.11.006","volume":"89","author":"F Gelsomino","year":"2014","unstructured":"Gelsomino F, et al. Targeting the MET gene for the treatment of non-small-cell lung cancer. Crit Rev Oncol\/Hematol. 2014;89(2):284\u201399.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"7511","key":"3981_CR89","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"CGAR Network","year":"2014","unstructured":"Network CGAR. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543.","journal-title":"Nature"},{"key":"3981_CR90","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.lungcan.2016.11.011","volume":"103","author":"T Reungwetwattana","year":"2017","unstructured":"Reungwetwattana T, et al. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable. Lung Cancer. 2017;103:27\u201337.","journal-title":"Lung Cancer"},{"issue":"10","key":"3981_CR91","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1158\/1078-0432.CCR-18-2814","volume":"25","author":"S Baltschukat","year":"2019","unstructured":"Baltschukat S, et al. Capmatinib (INC280) is active against models of non\u2013small cell lung cancer and other cancer types with defined mechanisms of MET activation. Clin Cancer Res. 2019;25(10):3164\u201375.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3981_CR92","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40265-020-01317-9","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A. Tepotinib: first approval. Drugs. 2020;80(8):829\u201333.","journal-title":"Drugs"},{"issue":"1","key":"3981_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cllc.2020.10.013","volume":"22","author":"N Haratake","year":"2021","unstructured":"Haratake N, Seto T. NTRK fusion-positive non\u2013small-cell lung cancer: the diagnosis and targeted therapy. Clin Lung Cancer. 2021;22(1):1\u20135.","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"3981_CR94","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/ng.2330","volume":"44","author":"Z Zhang","year":"2012","unstructured":"Zhang Z, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012;44(8):852\u201360.","journal-title":"Nat Genet"},{"issue":"4","key":"3981_CR95","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1158\/0008-5472.CAN-09-2997","volume":"70","author":"SJ Holland","year":"2010","unstructured":"Holland SJ, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 2010;70(4):1544\u201354.","journal-title":"Cancer Res"},{"issue":"4","key":"3981_CR96","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.cell.2020.09.044","volume":"183","author":"D Kim","year":"2020","unstructured":"Kim D, Xue JY, Lito P. Targeting KRAS (G12C): from inhibitory mechanism to modulation of antitumor effects in patients. Cell. 2020;183(4):850\u20139.","journal-title":"Cell"},{"issue":"3","key":"3981_CR97","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.lungcan.2009.11.020","volume":"69","author":"C Mao","year":"2010","unstructured":"Mao C, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer. 2010;69(3):272\u20138.","journal-title":"Lung Cancer"},{"issue":"7781","key":"3981_CR98","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, et al. The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217\u201323.","journal-title":"Nature"},{"issue":"1","key":"3981_CR99","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin J, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10(1):54\u201371.","journal-title":"Cancer Discov"},{"issue":"13","key":"3981_CR100","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, et al. KRASG12C Inhibition with Sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207\u201317.","journal-title":"N Engl J Med"},{"issue":"2","key":"3981_CR101","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3322\/caac.21597","volume":"70","author":"J Cortes","year":"2020","unstructured":"Cortes J, et al. Enhancing global access to cancer medicines. Cancer J Clin. 2020;70(2):105\u201324.","journal-title":"Cancer J Clin"},{"issue":"4","key":"3981_CR102","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/path.5902","volume":"257","author":"E Gadaleta","year":"2022","unstructured":"Gadaleta E, et al. Field cancerization in breast cancer. J Pathol. 2022;257(4):561\u201374.","journal-title":"J Pathol"},{"key":"3981_CR103","doi-asserted-by":"crossref","unstructured":"Tfayli AH et al. Locally advanced lung cancer.CA Cancer J Clin. 2021;71(6):461-465.","DOI":"10.3322\/caac.21698"},{"key":"3981_CR104","doi-asserted-by":"publisher","first-page":"1062679","DOI":"10.3389\/fimmu.2023.1062679","volume":"14","author":"T Mei","year":"2023","unstructured":"Mei T, et al. The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: a systematic review and network meta-analysis. Front Immunol. 2023;14:1062679.","journal-title":"Front Immunol"},{"issue":"4","key":"3981_CR105","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1093\/oncolo\/oyac267","volume":"28","author":"N Shi","year":"2023","unstructured":"Shi N, et al. Mobile health application-based interventions to improve self-management of chemotherapy-related symptoms among people with breast cancer who are undergoing chemotherapy: a systematic review. Oncologist. 2023;28(4):e175\u201382.","journal-title":"Oncologist"},{"key":"3981_CR106","doi-asserted-by":"publisher","first-page":"102512","DOI":"10.1016\/j.ctrv.2023.102512","volume":"115","author":"M Filetti","year":"2023","unstructured":"Filetti M, et al. Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis. Cancer Treat Rev. 2023;115:102512.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"3981_CR107","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-2600(20)30455-0","volume":"9","author":"Y Shi","year":"2021","unstructured":"Shi Y, et al. Efficacy, safety, and genetic analysis of Furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respiratory Med. 2021;9(8):829\u201339.","journal-title":"Lancet Respiratory Med"},{"issue":"2","key":"3981_CR108","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","volume":"70","author":"LB Kennedy","year":"2020","unstructured":"Kennedy LB, Salama AK. A review of cancer immunotherapy toxicity. Cancer J Clin. 2020;70(2):86\u2013104.","journal-title":"Cancer J Clin"},{"issue":"1","key":"3981_CR109","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3322\/caac.21702","volume":"72","author":"A Shimabukuro-Vornhagen","year":"2022","unstructured":"Shimabukuro-Vornhagen A, et al. Critical care management of chimeric antigen receptor T\u2010cell therapy recipients. Cancer J Clin. 2022;72(1):78\u201393.","journal-title":"Cancer J Clin"},{"key":"3981_CR110","doi-asserted-by":"publisher","first-page":"903562","DOI":"10.3389\/fimmu.2022.903562","volume":"13","author":"P Kandra","year":"2022","unstructured":"Kandra P, et al. Utility and drawbacks of chimeric antigen receptor T cell (CAR-T) therapy in lung cancer. Front Immunol. 2022;13:903562.","journal-title":"Front Immunol"},{"issue":"3","key":"3981_CR111","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","volume":"24","author":"SG Kroeze","year":"2023","unstructured":"Kroeze SG, et al. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC\u2013ESTRO oligocare consortium. Lancet Oncol. 2023;24(3):e121\u201332.","journal-title":"Lancet Oncol"},{"issue":"20","key":"3981_CR112","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.7150\/jca.26364","volume":"9","author":"H Zhuang","year":"2018","unstructured":"Zhuang H. Research progress on the impact of radiation on TKI resistance mechanisms in NSCLC. J Cancer. 2018;9(20):3797.","journal-title":"J Cancer"},{"key":"3981_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-01009-7","volume":"13","author":"Y Fu","year":"2020","unstructured":"Fu Y, et al. Abnormally activated OPN\/integrin \u03b1V\u03b23\/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer. J Hematol Oncol. 2020;13:1\u201315.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3981_CR114","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-022-01311-6","volume":"15","author":"K Shi","year":"2022","unstructured":"Shi K, et al. Emerging strategies to overcome resistance to third-generation EGFR inhibitors. J Hematol Oncol. 2022;15(1):94.","journal-title":"J Hematol Oncol"},{"issue":"18","key":"3981_CR115","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.3390\/cancers14184423","volume":"14","author":"J Li","year":"2022","unstructured":"Li J, et al. Emerging role of noncoding RNAs in EGFR TKI-resistant lung cancer. Cancers. 2022;14(18):4423.","journal-title":"Cancers"},{"key":"3981_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12917-020-02448-7","volume":"16","author":"SU Rahman","year":"2020","unstructured":"Rahman SU, et al. Tea polyphenols attenuate liver inflammation by modulating obesity-related genes and down-regulating COX-2 and iNOS expression in high fat-fed dogs. BMC Vet Res. 2020;16:1\u201312.","journal-title":"BMC Vet Res"},{"issue":"9","key":"3981_CR117","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/ijc.33399","volume":"148","author":"YL Wu","year":"2021","unstructured":"Wu YL, et al. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1\u2010positive locally advanced or metastatic non\u2013small\u2010cell lung cancer: KEYNOTE\u2010042 China study. Int J Cancer. 2021;148(9):2313\u201320.","journal-title":"Int J Cancer"},{"key":"3981_CR118","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lungcan.2020.11.018","volume":"151","author":"EB Garon","year":"2021","unstructured":"Garon EB, Kim JS, Govindan R. Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: a cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL. Lung Cancer. 2021;151:25\u20139.","journal-title":"Lung Cancer"},{"issue":"14","key":"3981_CR119","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel S, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non\u2013small-cell lung cancer. J Clin Oncol. 2020;38(14):1505\u201317.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3981_CR120","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jtho.2022.08.014","volume":"18","author":"LG Paz-Ares","year":"2023","unstructured":"Paz-Ares LG, et al. Safety of first-line nivolumab plus ipilimumab in patients with metastatic NSCLC: a pooled analysis of checkmate 227, checkmate 568, and checkmate 817. J Thorac Oncol. 2023;18(1):79\u201392.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"3981_CR121","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40164-023-00417-y","volume":"12","author":"S Mao","year":"2023","unstructured":"Mao S, et al. Molecular correlation of response to Pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials. Experimental Hematol Oncol. 2023;12(1):53.","journal-title":"Experimental Hematol Oncol"},{"key":"3981_CR122","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2165\/00063030-200822050-00003","volume":"22","author":"F Aires da Silva","year":"2008","unstructured":"Aires da Silva F, Corte-Real S, Goncalves J. Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs. BioDrugs. 2008;22:301\u201314.","journal-title":"BioDrugs"},{"key":"3981_CR123","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.addr.2020.07.003","volume":"154","author":"Y Matsumura","year":"2020","unstructured":"Matsumura Y. Cancer stromal targeting therapy to overcome the pitfall of EPR effect. Adv Drug Deliv Rev. 2020;154:142\u201350.","journal-title":"Adv Drug Deliv Rev"},{"key":"3981_CR124","doi-asserted-by":"crossref","unstructured":"Hock MB, et al. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. Springer; 2015.","DOI":"10.1208\/s12248-014-9684-6"},{"issue":"2","key":"3981_CR125","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/biology9020028","volume":"9","author":"D Zaytsev","year":"2020","unstructured":"Zaytsev D, et al. Rapid efficacy of Gemtuzumab Ozogamicin in refractory AML patients with pulmonary and kidney failure. Biology. 2020;9(2):28.","journal-title":"Biology"},{"key":"3981_CR126","doi-asserted-by":"crossref","unstructured":"Panowski S, et al. Site-specific antibody drug conjugates for cancer therapy. MAbs. Taylor & Francis; 2014;6(1):34-45.","DOI":"10.4161\/mabs.27022"},{"issue":"5","key":"3981_CR127","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1002\/jcp.27419","volume":"234","author":"M Abdollahpour-Alitappeh","year":"2019","unstructured":"Abdollahpour-Alitappeh M, et al. Antibody\u2013drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. J Cell Physiol. 2019;234(5):5628\u201342.","journal-title":"J Cell Physiol"},{"key":"3981_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01035-z","volume":"14","author":"C Criscitiello","year":"2021","unstructured":"Criscitiello C, Morganti S, Curigliano G. Antibody\u2013drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021;14:1\u201318.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"3981_CR129","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, et al. Antibody\u2013drug conjugates: smart chemotherapy delivery across tumor histologies. Cancer J Clin. 2022;72(2):165\u201382.","journal-title":"Cancer J Clin"},{"key":"3981_CR130","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1007\/s11095-015-1624-3","volume":"32","author":"M Damelin","year":"2015","unstructured":"Damelin M, et al. Evolving strategies for target selection for antibody-drug conjugates. Pharm Res. 2015;32:3494\u2013507.","journal-title":"Pharm Res"},{"issue":"4","key":"3981_CR131","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/bjc.2015.435","volume":"114","author":"N Diamantis","year":"2016","unstructured":"Diamantis N, Banerji U. Antibody-drug conjugates\u2014an emerging class of cancer treatment. Br J Cancer. 2016;114(4):362\u20137.","journal-title":"Br J Cancer"},{"issue":"2","key":"3981_CR132","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.canlet.2007.04.010","volume":"255","author":"YV Kovtun","year":"2007","unstructured":"Kovtun YV, Goldmacher VS. Cell killing by antibody\u2013drug conjugates. Cancer Lett. 2007;255(2):232\u201340.","journal-title":"Cancer Lett"},{"key":"3981_CR133","doi-asserted-by":"crossref","unstructured":"Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs. Taylor & Francis; 2013;5(1):13-21.","DOI":"10.4161\/mabs.22854"},{"issue":"9","key":"3981_CR134","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","volume":"76","author":"F Li","year":"2016","unstructured":"Li F, et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 2016;76(9):2710\u20139.","journal-title":"Cancer Res"},{"issue":"18","key":"3981_CR135","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","volume":"25","author":"S Coats","year":"2019","unstructured":"Coats S, et al. Antibody\u2013drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index. Clin Cancer Res. 2019;25(18):5441\u20138.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"3981_CR136","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1021\/ac970035q","volume":"69","author":"MM Siegel","year":"1997","unstructured":"Siegel MM, et al. Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption\/ionization mass spectrometry and electrospray ionization mass spectrometry. Anal Chem. 1997;69(14):2716\u201326.","journal-title":"Anal Chem"},{"issue":"3","key":"3981_CR137","doi-asserted-by":"publisher","first-page":"e1395127","DOI":"10.1080\/2162402X.2017.1395127","volume":"7","author":"RM Hoffmann","year":"2018","unstructured":"Hoffmann RM, et al. Antibody structure and engineering considerations for the design and function of antibody drug conjugates (ADCs). Oncoimmunology. 2018;7(3):e1395127.","journal-title":"Oncoimmunology"},{"issue":"10094","key":"3981_CR138","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"Prince HM, et al. Brentuximab Vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555\u201366.","journal-title":"Lancet"},{"issue":"1","key":"3981_CR139","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1021\/bc900315y","volume":"21","author":"HK Erickson","year":"2010","unstructured":"Erickson HK, et al. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody\u2009\u2013\u2009maytansinoid conjugates. Bioconjug Chem. 2010;21(1):84\u201392.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"3981_CR140","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/antib7010010","volume":"7","author":"AT Lucas","year":"2018","unstructured":"Lucas AT, et al. Factors affecting the Pharmacology of antibody\u2013drug conjugates. Antibodies. 2018;7(1):10.","journal-title":"Antibodies"},{"issue":"7","key":"3981_CR141","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/nbt.3274","volume":"33","author":"P Strop","year":"2015","unstructured":"Strop P, et al. Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat Biotechnol. 2015;33(7):694\u20136.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"3981_CR142","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/s41598-019-38745-x","volume":"9","author":"MJ Costa","year":"2019","unstructured":"Costa MJ, et al. Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates. Sci Rep. 2019;9(1):2443.","journal-title":"Sci Rep"},{"key":"3981_CR143","doi-asserted-by":"crossref","unstructured":"Wakileh GA et al. Molecular characterization of the CXCR4\/CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates. Experimental hematology & oncology, 2023. 12(1): p. 96.","DOI":"10.1186\/s40164-023-00460-9"},{"issue":"16","key":"3981_CR144","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1158\/0008-5472.CAN-15-0129","volume":"75","author":"AV Yurkovetskiy","year":"2015","unstructured":"Yurkovetskiy AV, et al. A polymer-based antibody\u2013vinca drug conjugate platform: characterization and preclinical efficacy. Cancer Res. 2015;75(16):3365\u201372.","journal-title":"Cancer Res"},{"key":"3981_CR145","doi-asserted-by":"publisher","first-page":"114932","DOI":"10.1016\/j.taap.2020.114932","volume":"392","author":"JK Simmons","year":"2020","unstructured":"Simmons JK, et al. Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through pegylation. Toxicol Appl Pharmcol. 2020;392:114932.","journal-title":"Toxicol Appl Pharmcol"},{"issue":"1","key":"3981_CR146","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41392-020-00247-y","volume":"5","author":"T Shao","year":"2020","unstructured":"Shao T, et al. Construction of paclitaxel-based antibody\u2013drug conjugates with a pegylated linker to achieve superior therapeutic index. Signal Transduct Target Therapy. 2020;5(1):132.","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"3981_CR147","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, et al. Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Therapy. 2022;7(1):93.","journal-title":"Signal Transduct Target Therapy"},{"issue":"3","key":"3981_CR148","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/biom10030360","volume":"10","author":"H Shim","year":"2020","unstructured":"Shim H. Bispecific antibodies and antibody\u2013drug conjugates for cancer therapy: technological considerations. Biomolecules. 2020;10(3):360.","journal-title":"Biomolecules"},{"issue":"24","key":"3981_CR149","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1158\/1078-0432.CCR-19-4051","volume":"26","author":"S Decary","year":"2020","unstructured":"Decary S, et al. Preclinical activity of SAR408701: a novel anti-CEACAM5\u2013maytansinoid antibody\u2013drug conjugate for the treatment of CEACAM5-positive epithelial tumors. Clin Cancer Res. 2020;26(24):6589\u201399.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3981_CR150","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4155\/tde.10.98","volume":"2","author":"VS Goldmacher","year":"2011","unstructured":"Goldmacher VS, Kovtun YV. Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther Deliv. 2011;2(3):397\u2013416.","journal-title":"Ther Deliv"},{"issue":"7","key":"3981_CR151","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.drudis.2013.11.004","volume":"19","author":"HL Perez","year":"2014","unstructured":"Perez HL, et al. Antibody-drug conjugates: current status and future directions. Drug Discov Today. 2014;19(7):869\u201381.","journal-title":"Drug Discov Today"},{"issue":"5","key":"3981_CR152","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1053\/j.seminoncol.2014.08.001","volume":"41","author":"F Mack","year":"2014","unstructured":"Mack F, Ritchie M, Sapra P. The next generation of antibody drug conjugates. Semin Oncol. 2014;41(5):637\u201352.","journal-title":"Semin Oncol"},{"issue":"9","key":"3981_CR153","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1158\/0008-5472.CAN-13-2990","volume":"74","author":"E Perrino","year":"2014","unstructured":"Perrino E, et al. Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res. 2014;74(9):2569\u201378.","journal-title":"Cancer Res"},{"issue":"7","key":"3981_CR154","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/bjc.2011.78","volume":"104","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, et al. A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br J Cancer. 2011;104(7):1106\u201315.","journal-title":"Br J Cancer"},{"issue":"3","key":"3981_CR155","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.pharmthera.2013.03.004","volume":"138","author":"P Sapra","year":"2013","unstructured":"Sapra P, Shor B. Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol Ther. 2013;138(3):452\u201369.","journal-title":"Pharmacol Ther"},{"key":"3981_CR156","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.drup.2014.11.001","volume":"18","author":"L Shefet-Carasso","year":"2015","unstructured":"Shefet-Carasso L, Benhar I. Antibody-targeted drugs and drug resistance\u2013challenges and solutions. Drug Resist Updat. 2015;18:36\u201346.","journal-title":"Drug Resist Updat"},{"issue":"20","key":"3981_CR157","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1158\/1078-0432.CCR-11-0485","volume":"17","author":"V Blanc","year":"2011","unstructured":"Blanc V, et al. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 2011;17(20):6448\u201358.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3981_CR158","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3253","volume":"9","author":"C Dumontet","year":"2010","unstructured":"Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9(10):790\u2013803.","journal-title":"Nat Rev Drug Discov"},{"issue":"19","key":"3981_CR159","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783\u201391.","journal-title":"N Engl J Med"},{"key":"3981_CR160","doi-asserted-by":"crossref","unstructured":"Del Re M et al. ErbB in NSCLC as a molecular target: current evidences and future directions. ESMO Open. 2020;5(4):e000724.","DOI":"10.1136\/esmoopen-2020-000724"},{"key":"3981_CR161","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-7219-7_1","volume":"1652","author":"Z Wang","year":"2017","unstructured":"Wang Z. ErbB receptors and cancer. Methods Mol Biol. 2017;1652:3\u201335.","journal-title":"Methods Mol Biol"},{"key":"3981_CR162","doi-asserted-by":"publisher","first-page":"101996","DOI":"10.1016\/j.ctrv.2020.101996","volume":"86","author":"M Jebbink","year":"2020","unstructured":"Jebbink M, et al. The force of HER2 - A druggable target in NSCLC? Cancer Treat Rev. 2020;86:101996.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"3981_CR163","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.trecan.2019.12.010","volume":"6","author":"S Garc\u00eda-Alonso","year":"2020","unstructured":"Garc\u00eda-Alonso S, Oca\u00f1a A, Pandiella A. Trastuzumab emtansine: mechanisms of action and Resistance, clinical Progress, and beyond. Trends Cancer. 2020;6(2):130\u201346.","journal-title":"Trends Cancer"},{"key":"3981_CR164","doi-asserted-by":"publisher","first-page":"j2930","DOI":"10.1136\/bmj.j2930","volume":"357","author":"Z Kmietowicz","year":"2017","unstructured":"Kmietowicz Z. NICE approves trastuzumab emtansine after deal with drug company. BMJ. 2017;357:j2930.","journal-title":"BMJ"},{"issue":"8","key":"3981_CR165","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.chembiol.2004.05.014","volume":"11","author":"A Sandmann","year":"2004","unstructured":"Sandmann A, Sasse F, M\u00fcller R. Identification and analysis of the core biosynthetic machinery of tubulysin, a potent cytotoxin with potential anticancer activity. Chem Biol. 2004;11(8):1071\u20139.","journal-title":"Chem Biol"},{"issue":"24","key":"3981_CR166","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","volume":"36","author":"BT Li","year":"2018","unstructured":"Li BT, et al. Ado-Trastuzumab emtansine for patients with HER2-Mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36(24):2532\u20137.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3981_CR167","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","volume":"10","author":"BT Li","year":"2020","unstructured":"Li BT, et al. HER2-Mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discov. 2020;10(5):674\u201387.","journal-title":"Cancer Discov"},{"issue":"2","key":"3981_CR168","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jtho.2017.10.032","volume":"13","author":"K Hotta","year":"2018","unstructured":"Hotta K, et al. A phase II study of trastuzumab emtansine in HER2-Positive Non-Small cell lung cancer. J Thorac Oncol. 2018;13(2):273\u20139.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"3981_CR169","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1158\/1078-0432.CCR-18-1590","volume":"25","author":"S Peters","year":"2019","unstructured":"Peters S, et al. Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-Overexpressing metastatic Non-Small cell lung cancer: Efficacy, Safety, and biomarkers. Clin Cancer Res. 2019;25(1):64\u201372.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3981_CR170","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1073\/pnas.0808930106","volume":"106","author":"SA Perera","year":"2009","unstructured":"Perera SA, et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and Rapamycin combination therapy. Proc Natl Acad Sci U S A. 2009;106(2):474\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"3981_CR171","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, et al. Trastuzumab Deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143\u201354.","journal-title":"N Engl J Med"},{"issue":"2","key":"3981_CR172","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40264-018-0775-7","volume":"42","author":"A Wolska-Washer","year":"2019","unstructured":"Wolska-Washer A, Robak T. Safety and tolerability of Antibody-Drug conjugates in cancer. Drug Saf. 2019;42(2):295\u2013314.","journal-title":"Drug Saf"},{"issue":"20","key":"3981_CR173","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, et al. DS-8201a, A novel HER2-Targeting ADC with a novel DNA topoisomerase I Inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097\u2013108.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3981_CR174","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li BT, et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell lung cancer. N Engl J Med. 2022;386(3):241\u201351.","journal-title":"N Engl J Med"},{"issue":"5","key":"3981_CR175","doi-asserted-by":"publisher","first-page":"100260","DOI":"10.1016\/j.esmoop.2021.100260","volume":"6","author":"M Riudavets","year":"2021","unstructured":"Riudavets M, et al. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open. 2021;6(5):100260.","journal-title":"ESMO Open"},{"issue":"1","key":"3981_CR176","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41523-023-00522-5","volume":"9","author":"J Zhang","year":"2023","unstructured":"Zhang J, et al. Phase I study of A166, an antibody\u2013drug conjugate in advanced HER2-expressing solid tumours. NPJ Breast Cancer. 2023;9(1):28.","journal-title":"NPJ Breast Cancer"},{"issue":"11","key":"3981_CR177","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1158\/1535-7163.MCT-19-0452","volume":"18","author":"S Koganemaru","year":"2019","unstructured":"Koganemaru S, et al. U3-1402, a novel HER3-Targeting Antibody-Drug Conjugate, for the treatment of colorectal cancer. Mol Cancer Ther. 2019;18(11):2043\u201350.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"3981_CR178","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1158\/1078-0432.CCR-09-1218","volume":"16","author":"MR Campbell","year":"2010","unstructured":"Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res. 2010;16(5):1373\u201383.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3981_CR179","first-page":"355","volume":"12","author":"R Mishra","year":"2018","unstructured":"Mishra R, et al. HER3 signaling and targeted therapy in cancer. Oncol Rev. 2018;12(1):355.","journal-title":"Oncol Rev"},{"issue":"1","key":"3981_CR180","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","volume":"12","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, et al. Efficacy and safety of patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small cell lung cancer. Cancer Discov. 2022;12(1):74\u201389.","journal-title":"Cancer Discov"},{"issue":"1","key":"3981_CR181","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-020-00881-7","volume":"13","author":"R Chen","year":"2020","unstructured":"Chen R, et al. Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol. 2020;13(1):58.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3981_CR182","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40164-024-00493-8","volume":"13","author":"L Zhou","year":"2024","unstructured":"Zhou L, et al. Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice. Exp Hematol Oncol. 2024;13(1):26.","journal-title":"Exp Hematol Oncol"},{"issue":"17","key":"3981_CR183","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","volume":"21","author":"AN Starodub","year":"2015","unstructured":"Starodub AN, et al. First-in-Human trial of a novel Anti-Trop-2 Antibody-SN-38 Conjugate, sacituzumab Govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21(17):3870\u20138.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3981_CR184","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Ann Oncol. 2021;32(6):746\u201356.","journal-title":"Ann Oncol"},{"issue":"21","key":"3981_CR185","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2217\/fon-2023-0230","volume":"19","author":"BP Levy","year":"2023","unstructured":"Levy BP, et al. TROPION-Lung08: phase III study of Datopotamab Deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncol. 2023;19(21):1461\u201372.","journal-title":"Future Oncol"},{"issue":"10","key":"3981_CR186","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1093\/annonc\/mdy334","volume":"29","author":"JK Sabari","year":"2018","unstructured":"Sabari JK, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018;29(10):2085\u201391.","journal-title":"Ann Oncol"},{"key":"3981_CR187","doi-asserted-by":"crossref","unstructured":"Lee JK, et al. Characterization of non-small-cell lung cancers with MET exon 14 skipping alterations detected in tissue or liquid: clinicogenomics and real-world treatment patterns. JCO Precis Oncol. 2021;5:PO.21.00122.","DOI":"10.1200\/PO.21.00122"},{"issue":"4","key":"3981_CR188","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jtho.2020.11.017","volume":"16","author":"A Kron","year":"2021","unstructured":"Kron A, et al. Genetic heterogeneity of MET-Aberrant NSCLC and its impact on the outcome of immunotherapy. J Thorac Oncol. 2021;16(4):572\u201382.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3981_CR189","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S1470-2045(19)30859-9","volume":"21","author":"S Schmid","year":"2020","unstructured":"Schmid S, Fr\u00fch M, Peters S. Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice? Lancet Oncol. 2020;21(3):320\u20132.","journal-title":"Lancet Oncol"},{"issue":"33","key":"3981_CR190","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1200\/JCO.2018.78.7697","volume":"36","author":"JH Strickler","year":"2018","unstructured":"Strickler JH, et al. First-in-Human phase I, Dose-Escalation and -Expansion study of Telisotuzumab Vedotin, an Antibody\u2013Drug conjugate targeting c-Met, in patients with advanced solid tumors. J Clin Oncol. 2018;36(33):3298\u2013306.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3981_CR191","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.cllc.2020.09.013","volume":"22","author":"SN Waqar","year":"2021","unstructured":"Waqar SN, et al. A phase II study of Telisotuzumab Vedotin in patients with c-MET-positive stage IV or recurrent squamous cell lung cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clin Lung Cancer. 2021;22(3):170\u20137.","journal-title":"Clin Lung Cancer"},{"issue":"21","key":"3981_CR192","doi-asserted-by":"publisher","first-page":"5781","DOI":"10.1158\/1078-0432.CCR-21-0765","volume":"27","author":"DR Camidge","year":"2021","unstructured":"Camidge DR, et al. Phase I study of 2- or 3-Week dosing of Telisotuzumab Vedotin, an Antibody-Drug conjugate targeting c-Met, monotherapy in patients with advanced Non-Small cell lung carcinoma. Clin Cancer Res. 2021;27(21):5781\u201392.","journal-title":"Clin Cancer Res"},{"issue":"302","key":"3981_CR193","doi-asserted-by":"publisher","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","volume":"7","author":"LR Saunders","year":"2015","unstructured":"Saunders LR, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7(302):302ra136.","journal-title":"Sci Transl Med"},{"issue":"1","key":"3981_CR194","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","volume":"12","author":"DH Owen","year":"2019","unstructured":"Owen DH, et al. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol. 2019;12(1):61.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3981_CR195","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","volume":"16","author":"CM Rudin","year":"2023","unstructured":"Rudin CM, et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol. 2023;16(1):66.","journal-title":"J Hematol Oncol"},{"issue":"29","key":"3981_CR196","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","volume":"37","author":"JE Rosenberg","year":"2019","unstructured":"Rosenberg JE, et al. Pivotal trial of enfortumab Vedotin in urothelial carcinoma after platinum and Anti-Programmed death 1\/Programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592\u2013600.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3981_CR197","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","volume":"18","author":"CM Rudin","year":"2017","unstructured":"Rudin CM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18(1):42\u201351.","journal-title":"Lancet Oncol"},{"issue":"23","key":"3981_CR198","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","volume":"25","author":"D Morgensztern","year":"2019","unstructured":"Morgensztern D, et al. Efficacy and safety of rovalpituzumab Tesirine in Third-Line and beyond patients with DLL3-Expressing, Relapsed\/Refractory Small-Cell lung cancer: results from the phase II TRINITY study. Clin Cancer Res. 2019;25(23):6958\u201366.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3981_CR199","doi-asserted-by":"publisher","first-page":"100204","DOI":"10.1016\/j.esmoop.2021.100204","volume":"6","author":"E Adams","year":"2021","unstructured":"Adams E, et al. Sacituzumab Govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape. ESMO Open. 2021;6(4):100204.","journal-title":"ESMO Open"},{"key":"3981_CR200","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jconrel.2022.02.026","volume":"344","author":"YS Cho","year":"2022","unstructured":"Cho YS, et al. Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer. J Control Release. 2022;344:26\u201338.","journal-title":"J Control Release"},{"key":"3981_CR201","doi-asserted-by":"crossref","unstructured":"Heh E et al. Peptide drug conjugates and their role in cancer therapy. Int J Mol Sci. 2023;24(1):829.","DOI":"10.3390\/ijms24010829"},{"key":"3981_CR202","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3389\/fchem.2020.00571","volume":"8","author":"P Hoppenz","year":"2020","unstructured":"Hoppenz P, Els-Heindl S, Beck-Sickinger AG. Peptide-Drug conjugates and their targets in advanced cancer therapies. Front Chem. 2020;8:571.","journal-title":"Front Chem"},{"issue":"1","key":"3981_CR203","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12951-018-0362-1","volume":"16","author":"K Kalimuthu","year":"2018","unstructured":"Kalimuthu K, et al. Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells. J Nanobiotechnol. 2018;16(1):34.","journal-title":"J Nanobiotechnol"},{"issue":"6","key":"3981_CR204","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S1470-2045(18)30193-1","volume":"19","author":"V Gregorc","year":"2018","unstructured":"Gregorc V, et al. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2018;19(6):799\u2013811.","journal-title":"Lancet Oncol"},{"issue":"34","key":"3981_CR205","doi-asserted-by":"publisher","first-page":"9894","DOI":"10.1002\/anie.201603488","volume":"55","author":"N Cox","year":"2016","unstructured":"Cox N, et al. Integrin-Targeting Knottin Peptide-Drug conjugates are potent inhibitors of tumor cell proliferation. Angew Chem Int Ed Engl. 2016;55(34):9894\u20137.","journal-title":"Angew Chem Int Ed Engl"},{"key":"3981_CR206","doi-asserted-by":"publisher","first-page":"1115495","DOI":"10.3389\/fchem.2023.1115495","volume":"11","author":"M Zhang","year":"2023","unstructured":"Zhang M, Xu H. Peptide-assembled nanoparticles targeting tumor cells and tumor microenvironment for cancer therapy. Front Chem. 2023;11:1115495.","journal-title":"Front Chem"},{"issue":"5","key":"3981_CR207","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1021\/acs.jmedchem.7b01837","volume":"61","author":"AF Salem","year":"2018","unstructured":"Salem AF, et al. Reduction of Circulating cancer cells and metastases in Breast-Cancer models by a potent EphA2-Agonistic Peptide-Drug conjugate. J Med Chem. 2018;61(5):2052\u201361.","journal-title":"J Med Chem"},{"key":"3981_CR208","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.csbj.2021.02.002","volume":"19","author":"A Toplak","year":"2021","unstructured":"Toplak A, et al. From thiol-subtilisin to omniligase: design and structure of a broadly applicable peptide ligase. Comput Struct Biotechnol J. 2021;19:1277\u201387.","journal-title":"Comput Struct Biotechnol J"},{"issue":"5","key":"3981_CR209","first-page":"2515","volume":"40","author":"W Yan","year":"2018","unstructured":"Yan W, et al. Identification of MMP9 as a novel key gene in mantle cell lymphoma based on bioinformatic analysis and design of Cyclic peptides as MMP9 inhibitors based on molecular Docking. Oncol Rep. 2018;40(5):2515\u201324.","journal-title":"Oncol Rep"},{"key":"3981_CR210","doi-asserted-by":"publisher","first-page":"119553","DOI":"10.1016\/j.biomaterials.2019.119553","volume":"228","author":"J Ge","year":"2020","unstructured":"Ge J, et al. Radiolabeling nanomaterials for multimodality imaging: new insights into nuclear medicine and cancer diagnosis. Biomaterials. 2020;228:119553.","journal-title":"Biomaterials"},{"issue":"31","key":"3981_CR211","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.2174\/0929867324666170404142840","volume":"24","author":"L Ma","year":"2017","unstructured":"Ma L, et al. Peptide-drug conjugate: a novel drug design approach. Curr Med Chem. 2017;24(31):3373\u201396.","journal-title":"Curr Med Chem"},{"issue":"2","key":"3981_CR212","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ijc.21089","volume":"116","author":"YW Chang","year":"2005","unstructured":"Chang YW, et al. CD13 (aminopeptidase N) can associate with tumor-associated antigen L6 and enhance the motility of human lung cancer cells. Int J Cancer. 2005;116(2):243\u201352.","journal-title":"Int J Cancer"},{"issue":"18","key":"3981_CR213","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.3390\/ijms20184511","volume":"20","author":"B Valentinis","year":"2019","unstructured":"Valentinis B, et al. Mechanism of action of the tumor vessel targeting agent NGR-hTNF: role of both NGR peptide and hTNF in cell binding and signaling. Int J Mol Sci. 2019;20(18):4511.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3981_CR214","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2174\/1574892812666170203151930","volume":"12","author":"D Arosio","year":"2017","unstructured":"Arosio D, et al. Integrin-targeted peptide-and peptidomimetic-drug conjugates for the treatment of tumors. Recent Pat Anti-cancer Drug Discov. 2017;12(2):148\u201368.","journal-title":"Recent Pat Anti-cancer Drug Discov"},{"issue":"9","key":"3981_CR215","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/cancers9090116","volume":"9","author":"M Nieberler","year":"2017","unstructured":"Nieberler M, et al. Exploring the role of RGD-recognizing integrins in cancer. Cancers. 2017;9(9):116.","journal-title":"Cancers"},{"issue":"27","key":"3981_CR216","doi-asserted-by":"publisher","first-page":"19307","DOI":"10.18632\/oncotarget.25028","volume":"9","author":"C Provost","year":"2018","unstructured":"Provost C, et al. Comparison and evaluation of two RGD peptides labelled with 68Ga or 18F for PET imaging of angiogenesis in animal models of human glioblastoma or lung carcinoma. Oncotarget. 2018;9(27):19307.","journal-title":"Oncotarget"},{"issue":"2","key":"3981_CR217","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"13","key":"3981_CR218","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1007\/s00259-021-05370-8","volume":"48","author":"Q Liu","year":"2021","unstructured":"Liu Q, et al. Head-to-head comparison of 68Ga-DOTATATE PET\/CT and 18F-FDG PET\/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study. Eur J Nucl Med Mol Imaging. 2021;48(13):4386\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"3981_CR219","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2967\/jnumed.119.235093","volume":"61","author":"W Zhu","year":"2020","unstructured":"Zhu W, et al. Head-to-head comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET\/CT in patients with metastatic, well-differentiated neuroendocrine tumors: a prospective study. J Nucl Med. 2020;61(6):897\u2013903.","journal-title":"J Nucl Med"},{"key":"3981_CR220","doi-asserted-by":"publisher","first-page":"v174","DOI":"10.1093\/annonc\/mdz244.026","volume":"30","author":"N Cook","year":"2019","unstructured":"Cook N, et al. Pharmacokinetic (PK) assessment of BT1718: A phase I\/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid tumours. Ann Oncol. 2019;30:v174.","journal-title":"Ann Oncol"},{"issue":"2","key":"3981_CR221","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.apsb.2022.07.020","volume":"13","author":"C Fu","year":"2023","unstructured":"Fu C, et al. Peptide\u2013drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope? Acta Pharm Sinica B. 2023;13(2):498\u2013516.","journal-title":"Acta Pharm Sinica B"},{"issue":"7","key":"3981_CR222","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1021\/acs.chemrev.8b00006","volume":"118","author":"F Seidi","year":"2018","unstructured":"Seidi F, Jenjob R, Crespy D. Designing smart polymer conjugates for controlled release of payloads. Chem Rev. 2018;118(7):3965\u20134036.","journal-title":"Chem Rev"},{"issue":"21","key":"3981_CR223","doi-asserted-by":"publisher","first-page":"7232","DOI":"10.3390\/molecules27217232","volume":"27","author":"VP Chavda","year":"2022","unstructured":"Chavda VP, et al. Peptide-drug conjugates: a new hope for cancer management. Molecules. 2022;27(21):7232.","journal-title":"Molecules"},{"issue":"2","key":"3981_CR224","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1021\/acsptsci.3c00269","volume":"7","author":"SFA Rizvi","year":"2024","unstructured":"Rizvi SFA, et al. Peptide-drug conjugates: design, chemistry, and drug delivery system as a novel cancer theranostic. ACS Pharmacol Translational Sci. 2024;7(2):309\u201334.","journal-title":"ACS Pharmacol Translational Sci"},{"issue":"3","key":"3981_CR225","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1039\/D0CS00556H","volume":"50","author":"BM Cooper","year":"2021","unstructured":"Cooper BM, et al. Peptides as a platform for targeted therapeutics for cancer: peptide\u2013drug conjugates (PDCs). Chem Soc Rev. 2021;50(3):1480\u201394.","journal-title":"Chem Soc Rev"},{"key":"3981_CR226","doi-asserted-by":"crossref","unstructured":"Kitson L. S., Targeted therapy towards cancer\u2014a perspective. Anti-Cancer Agents Med Chem (Formerly current medicinal chemistry-Anti-Cancer agents). 2017;17(3):311\u20137.","DOI":"10.2174\/1871520616666160926115008"},{"issue":"6","key":"3981_CR227","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/PPO.0000000000000625","volume":"28","author":"L Martiniova","year":"2022","unstructured":"Martiniova L, et al. The role of radiolabeled monoclonal antibodies in cancer imaging and ADC treatment. Cancer J. 2022;28(6):446\u201353.","journal-title":"Cancer J"},{"issue":"3","key":"3981_CR228","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2174\/18744710113066660023","volume":"6","author":"A Dash","year":"2013","unstructured":"Dash A, Knapp FF, Ra M, Pillai. Targeted radionuclide therapy-an overview. Curr Radiopharmaceuticals. 2013;6(3):152\u201380.","journal-title":"Curr Radiopharmaceuticals"},{"issue":"6","key":"3981_CR229","doi-asserted-by":"publisher","first-page":"769","DOI":"10.4155\/tde.11.41","volume":"2","author":"S Prabhu","year":"2011","unstructured":"Prabhu S, et al. Antibody delivery of drugs and radionuclides: factors influencing clinical Pharmacology. Therapeutic Delivery. 2011;2(6):769\u201391.","journal-title":"Therapeutic Delivery"},{"issue":"11","key":"3981_CR230","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1021\/acs.molpharmaceut.0c00703","volume":"17","author":"AL Lakes","year":"2020","unstructured":"Lakes AL, et al. Evaluating 225Ac and 177Lu radioimmunoconjugates against antibody\u2013drug conjugates for small-cell lung cancer. Mol Pharm. 2020;17(11):4270\u20139.","journal-title":"Mol Pharm"},{"issue":"4","key":"3981_CR231","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.nucmedbio.2006.03.003","volume":"33","author":"K Zhang","year":"2006","unstructured":"Zhang K, et al. Radionuclide imaging of small-cell lung cancer (SCLC) using 99mTc-labeled neurotensin peptide 8\u201313. Nucl Med Biol. 2006;33(4):505\u201312.","journal-title":"Nucl Med Biol"},{"key":"3981_CR232","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00432-015-2067-2","volume":"142","author":"W Li","year":"2016","unstructured":"Li W, et al. Radionuclide therapy using 131 I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression. J Cancer Res Clin Oncol. 2016;142:619\u201332.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"3981_CR233","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1007\/s00259-023-06174-8","volume":"50","author":"T Zhu","year":"2023","unstructured":"Zhu T, et al. Radionuclide-based theranostics\u2014A promising strategy for lung cancer. Eur J Nucl Med Mol Imaging. 2023;50(8):2353\u201374.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"22","key":"3981_CR234","doi-asserted-by":"publisher","first-page":"8751","DOI":"10.1021\/acs.jmedchem.5b00457","volume":"58","author":"G Casi","year":"2015","unstructured":"Casi G, Neri D. Antibody\u2013drug conjugates and small molecule\u2013drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents: miniperspective. J Med Chem. 2015;58(22):8751\u201361.","journal-title":"J Med Chem"},{"issue":"3","key":"3981_CR235","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd4519","volume":"14","author":"M Srinivasarao","year":"2015","unstructured":"Srinivasarao M, Galliford CV, Low PS. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discovery. 2015;14(3):203\u201319.","journal-title":"Nat Rev Drug Discovery"},{"issue":"3","key":"3981_CR236","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3904\/kjim.2014.031","volume":"31","author":"HK Min","year":"2016","unstructured":"Min HK, et al. Trastuzumab-associated autoimmune thyroid disease in a patient with metastatic breast cancer. Korean J Intern Med. 2016;31(3):608.","journal-title":"Korean J Intern Med"},{"issue":"4","key":"3981_CR237","doi-asserted-by":"publisher","first-page":"A439","DOI":"10.1016\/j.chest.2018.08.400","volume":"154","author":"A Alkhayat","year":"2018","unstructured":"Alkhayat A, et al. Brentuximab-induced pneumonitis and acute respiratory failure. Chest. 2018;154(4):A439\u201340.","journal-title":"Chest"},{"issue":"2","key":"3981_CR238","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1158\/1535-7163.MCT-11-0566","volume":"11","author":"R Kurzrock","year":"2012","unstructured":"Kurzrock R, et al. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther. 2012;11(2):308\u201316.","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"3981_CR239","doi-asserted-by":"publisher","first-page":"5566","DOI":"10.1158\/0008-5472.CAN-12-1683","volume":"72","author":"AA Manzoor","year":"2012","unstructured":"Manzoor AA, et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res. 2012;72(21):5566\u201375.","journal-title":"Cancer Res"},{"issue":"11","key":"3981_CR240","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","volume":"7","author":"RK Jain","year":"2010","unstructured":"Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Reviews Clin Oncol. 2010;7(11):653\u201364.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"10","key":"3981_CR241","doi-asserted-by":"publisher","first-page":"8573","DOI":"10.1021\/nn402644g","volume":"7","author":"E Vlashi","year":"2013","unstructured":"Vlashi E, et al. Effect of folate-targeted nanoparticle size on their rates of penetration into solid tumors. ACS Nano. 2013;7(10):8573\u201382.","journal-title":"ACS Nano"},{"issue":"6","key":"3981_CR242","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1021\/bc400131a","volume":"24","author":"LE Kelderhouse","year":"2013","unstructured":"Kelderhouse LE, et al. Development of tumor-targeted near infrared probes for fluorescence guided surgery. Bioconjug Chem. 2013;24(6):1075\u201380.","journal-title":"Bioconjug Chem"},{"key":"3981_CR243","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0624-2","volume":"11","author":"F Rossari","year":"2018","unstructured":"Rossari F, Minutolo F, Orciuolo E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol. 2018;11:1\u201314.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"3981_CR244","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1021\/bc2005522","volume":"23","author":"IR Vlahov","year":"2012","unstructured":"Vlahov IR, Leamon CP. Engineering folate\u2013drug conjugates to target cancer: from chemistry to clinic. Bioconjug Chem. 2012;23(7):1357\u201369.","journal-title":"Bioconjug Chem"},{"issue":"9","key":"3981_CR245","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.ejca.2008.12.022","volume":"45","author":"TE Ciuleanu","year":"2009","unstructured":"Ciuleanu TE, et al. A randomised phase III trial of Glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer. 2009;45(9):1589\u201396.","journal-title":"Eur J Cancer"},{"issue":"2","key":"3981_CR246","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/bjp.2008.260","volume":"155","author":"A R\u00e9gina","year":"2008","unstructured":"R\u00e9gina A, et al. Antitumour activity of ANG1005, a conjugate between Paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol. 2008;155(2):185\u201397.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"3981_CR247","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.maturitas.2012.01.016","volume":"73","author":"V Sanna","year":"2012","unstructured":"Sanna V, Sechi M. Nanoparticle therapeutics for prostate cancer treatment. Maturitas. 2012;73(1):27\u201332.","journal-title":"Maturitas"},{"issue":"5","key":"3981_CR248","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/med.20238","volume":"32","author":"A Corti","year":"2012","unstructured":"Corti A, et al. Targeted drug delivery and penetration into solid tumors. Med Res Rev. 2012;32(5):1078\u201391.","journal-title":"Med Res Rev"},{"issue":"1","key":"3981_CR249","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1078-0432.CCR-08-0132","volume":"15","author":"U Banerji","year":"2009","unstructured":"Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res. 2009;15(1):9\u201314.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"3981_CR250","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-11-2967","volume":"18","author":"T Shimamura","year":"2012","unstructured":"Shimamura T, et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non\u2013small cell lung cancer. Clin Cancer Res. 2012;18(18):4973\u201385.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3981_CR251","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2174\/156652412803306729","volume":"12","author":"S Alarcon","year":"2012","unstructured":"Alarcon S, et al. Tumor-intrinsic and tumor-extrinsic factors impacting hsp90-targeted therapy. Curr Mol Med. 2012;12(9):1125\u201341.","journal-title":"Curr Mol Med"},{"issue":"2","key":"3981_CR252","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.molcel.2013.12.007","volume":"53","author":"M Mollapour","year":"2014","unstructured":"Mollapour M, et al. Asymmetric Hsp90 N domain sumoylation recruits Aha1 and ATP-competitive inhibitors. Mol Cell. 2014;53(2):317\u201329.","journal-title":"Mol Cell"},{"issue":"20","key":"3981_CR253","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-15-3068","volume":"22","author":"AV Gaponova","year":"2016","unstructured":"Gaponova AV, et al. A novel HSP90 Inhibitor\u2013Drug conjugate to SN38 is highly effective in small cell lung cancer. Clin Cancer Res. 2016;22(20):5120\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3981_CR254","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1021\/bc400441s","volume":"25","author":"CP Leamon","year":"2014","unstructured":"Leamon CP, et al. Folate\u2013vinca alkaloid conjugates for cancer therapy: A structure\u2013activity relationship. Bioconjug Chem. 2014;25(3):560\u20138.","journal-title":"Bioconjug Chem"},{"issue":"12","key":"3981_CR255","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1177\/0091270009339740","volume":"49","author":"J Li","year":"2009","unstructured":"Li J, et al. Clinical pharmacokinetics and Exposure-Toxicity relationship of a Folate\u2010Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol. 2009;49(12):1467\u201376.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"3981_CR256","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1021\/jo100448q","volume":"75","author":"IR Vlahov","year":"2010","unstructured":"Vlahov IR, et al. Carbohydrate-based synthetic approach to control toxicity profiles of folate\u2009\u2013\u2009drug conjugates. J Org Chem. 2010;75(11):3685\u201391.","journal-title":"J Org Chem"},{"issue":"5","key":"3981_CR257","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1021\/mp070049c","volume":"4","author":"CP Leamon","year":"2007","unstructured":"Leamon CP, et al. Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol Pharm. 2007;4(5):659\u201367.","journal-title":"Mol Pharm"},{"issue":"4","key":"3981_CR258","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3390\/jcm10040838","volume":"10","author":"J Dugal-Tessier","year":"2021","unstructured":"Dugal-Tessier J, Thirumalairajan S, Jain N. Antibody-oligonucleotide conjugates: a twist to antibody-drug conjugates. J Clin Med. 2021;10(4):838.","journal-title":"J Clin Med"},{"issue":"3","key":"3981_CR259","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jcyt.2020.01.003","volume":"22","author":"MJ Frank","year":"2020","unstructured":"Frank MJ, et al. A novel antibody-cell conjugation method to enhance and characterize cytokine-induced killer cells. Cytotherapy. 2020;22(3):135\u201343.","journal-title":"Cytotherapy"},{"issue":"11","key":"3981_CR260","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.3390\/cancers13112724","volume":"13","author":"H-K Li","year":"2021","unstructured":"Li H-K, et al. A novel off-the-shelf trastuzumab-armed NK cell therapy (ACE1702) using antibody-cell-conjugation technology. Cancers. 2021;13(11):2724.","journal-title":"Cancers"},{"issue":"13","key":"3981_CR261","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1021\/acs.biochem.0c00860","volume":"60","author":"K Dutta","year":"2021","unstructured":"Dutta K, et al. Disulfide bridging strategies in viral and nonviral platforms for nucleic acid delivery. Biochemistry. 2021;60(13):966\u201390.","journal-title":"Biochemistry"},{"issue":"9","key":"3981_CR262","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1021\/acs.molpharmaceut.2c00392","volume":"19","author":"S Fang","year":"2022","unstructured":"Fang S, et al. Design and characterization of immune-stimulating Imidazo [4, 5-c] Quinoline antibody-drug conjugates. Mol Pharm. 2022;19(9):3228\u201341.","journal-title":"Mol Pharm"},{"issue":"1","key":"3981_CR263","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","volume":"2","author":"SE Ackerman","year":"2021","unstructured":"Ackerman SE, et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat Cancer. 2021;2(1):18\u201333.","journal-title":"Nat Cancer"},{"key":"3981_CR264","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s00109-006-0084-y","volume":"84","author":"S Uematsu","year":"2006","unstructured":"Uematsu S, Akira S. Toll-like receptors and innate immunity. J Mol Med. 2006;84:712\u201325.","journal-title":"J Mol Med"},{"issue":"11","key":"3981_CR265","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.3390\/cancers13112695","volume":"13","author":"A Amouzegar","year":"2021","unstructured":"Amouzegar A, et al. STING agonists as cancer therapeutics. Cancers. 2021;13(11):2695.","journal-title":"Cancers"},{"issue":"21","key":"3981_CR266","doi-asserted-by":"publisher","first-page":"15716","DOI":"10.1021\/acs.jmedchem.1c00961","volume":"64","author":"L He","year":"2021","unstructured":"He L, et al. Immune modulating antibody\u2013drug conjugate (IM-ADC) for cancer immunotherapy. J Med Chem. 2021;64(21):15716\u201326.","journal-title":"J Med Chem"},{"issue":"2","key":"3981_CR267","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s11010-020-03967-5","volume":"476","author":"F Shi","year":"2021","unstructured":"Shi F, et al. Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response. Mol Cell Biochem. 2021;476(2):1015\u201324.","journal-title":"Mol Cell Biochem"},{"issue":"8","key":"3981_CR268","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3390\/pharmaceutics14081524","volume":"14","author":"L Jolivet","year":"2022","unstructured":"Jolivet L, et al. Intra-Domain cysteines (IDC), a new strategy for the development of original antibody Fragment\u2013Drug conjugates (FDCs). Pharmaceutics. 2022;14(8):1524.","journal-title":"Pharmaceutics"},{"issue":"4","key":"3981_CR269","first-page":"237","volume":"3","author":"MP Deonarain","year":"2020","unstructured":"Deonarain MP, Xue Q. Tackling solid tumour therapy with small-format drug conjugates. Antib Ther. 2020;3(4):237\u201345.","journal-title":"Antib Ther"},{"issue":"9","key":"3981_CR270","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.str.2015.06.015","volume":"23","author":"GP Subedi","year":"2015","unstructured":"Subedi GP, Barb AW. The structural role of antibody N-glycosylation in receptor interactions. Structure. 2015;23(9):1573\u201383.","journal-title":"Structure"},{"issue":"12","key":"3981_CR271","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.3390\/pharmaceutics14122781","volume":"14","author":"Y Sun","year":"2022","unstructured":"Sun Y, et al. Artificial base-directed in vivo formulation of aptamer\u2013drug conjugates with albumin for long circulation and targeted delivery. Pharmaceutics. 2022;14(12):2781.","journal-title":"Pharmaceutics"},{"key":"3981_CR272","doi-asserted-by":"publisher","first-page":"1053984","DOI":"10.3389\/fcell.2022.1053984","volume":"10","author":"Y Li","year":"2022","unstructured":"Li Y, et al. Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers. Front Cell Dev Biology. 2022;10:1053984.","journal-title":"Front Cell Dev Biology"},{"issue":"11","key":"3981_CR273","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1021\/acs.bioconjchem.5b00291","volume":"26","author":"G Zhu","year":"2015","unstructured":"Zhu G, Niu G, Chen X. Aptamer\u2013drug Conjugates Bioconjug Chem. 2015;26(11):2186\u201397.","journal-title":"Aptamer\u2013drug Conjugates Bioconjug Chem"},{"issue":"7","key":"3981_CR274","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1021\/acs.bioconjchem.2c00177","volume":"33","author":"SS Matikonda","year":"2022","unstructured":"Matikonda SS, et al. Structure\u2013activity relationships of antibody-drug conjugates: a systematic review of chemistry on the trastuzumab scaffold. Bioconjug Chem. 2022;33(7):1241\u201353.","journal-title":"Bioconjug Chem"},{"key":"3981_CR275","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","volume":"200","author":"PK Mahalingaiah","year":"2019","unstructured":"Mahalingaiah PK, et al. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther. 2019;200:110\u201325.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"3981_CR276","first-page":"707","volume":"34","author":"P Wu","year":"2023","unstructured":"Wu P, et al. Optimizing conjugation Chemistry, antibody conjugation Site, and surface density in antibody\u2013Nanogel conjugates (ANCs) for Cell-Specific drug delivery. Bioconjug Chem. 2023;34(4):707\u201318.","journal-title":"Bioconjug Chem"},{"issue":"11","key":"3981_CR277","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","volume":"40","author":"R Colombo","year":"2022","unstructured":"Colombo R, Rich JR. The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell. 2022;40(11):1255\u201363.","journal-title":"Cancer Cell"},{"issue":"20","key":"3981_CR278","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.3390\/molecules25204764","volume":"25","author":"U Hafeez","year":"2020","unstructured":"Hafeez U, et al. Antibody\u2013drug conjugates for cancer therapy. Molecules. 2020;25(20):4764.","journal-title":"Molecules"},{"key":"3981_CR279","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10928-016-9495-8","volume":"43","author":"AP Singh","year":"2016","unstructured":"Singh AP, Sharma S, Shah DK. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates. J Pharmacokinet Pharmacodyn. 2016;43:567\u201382.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"3981_CR280","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/cancers15041278","volume":"15","author":"RO Abelman","year":"2023","unstructured":"Abelman RO, et al. Mechanisms of resistance to antibody\u2013drug conjugates. Cancers. 2023;15(4):1278.","journal-title":"Cancers"},{"issue":"4","key":"3981_CR281","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","volume":"14","author":"F Loganzo","year":"2015","unstructured":"Loganzo F, et al. Tumor cells chronically treated with a trastuzumab\u2013maytansinoid antibody\u2013drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015;14(4):952\u201363.","journal-title":"Mol Cancer Ther"},{"issue":"7782","key":"3981_CR282","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299\u2013309.","journal-title":"Nature"},{"issue":"20","key":"3981_CR283","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","volume":"10","author":"KJ Hamblett","year":"2004","unstructured":"Hamblett KJ, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063\u201370.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3981_CR284","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nchem.2415","volume":"8","author":"V Chudasama","year":"2016","unstructured":"Chudasama V, Maruani A, Caddick S. Recent advances in the construction of antibody\u2013drug conjugates. Nat Chem. 2016;8(2):114\u20139.","journal-title":"Nat Chem"},{"key":"3981_CR285","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s10529-016-2160-x","volume":"38","author":"R Bakhtiar","year":"2016","unstructured":"Bakhtiar R. Antibody drug conjugates. Biotechnol Lett. 2016;38:1655\u201364.","journal-title":"Biotechnol Lett"},{"issue":"10200","key":"3981_CR286","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","volume":"394","author":"CH Chau","year":"2019","unstructured":"Chau CH, Steeg PS, Figg WD. Antibody\u2013drug conjugates for cancer. Lancet. 2019;394(10200):793\u2013804.","journal-title":"Lancet"},{"issue":"1","key":"3981_CR287","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10555-024-10231-5","volume":"44","author":"S-C Tang","year":"2025","unstructured":"Tang S-C, et al. Influence of antibody\u2013drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis. Cancer Metastasis Rev. 2025;44(1):18.","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"3981_CR288","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, et al. Strategies and challenges for the next generation of antibody\u2013drug conjugates. Nat Rev Drug Discovery. 2017;16(5):315\u201337.","journal-title":"Nat Rev Drug Discovery"},{"key":"3981_CR289","doi-asserted-by":"crossref","unstructured":"Brun M-P, Gauzy-Lazo L. Protocols for lysine conjugation. Methods Mol Biol. 2013;1045:173-87.","DOI":"10.1007\/978-1-62703-541-5_10"},{"issue":"7","key":"3981_CR290","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/14712598.2021.1846714","volume":"21","author":"Y Matsuda","year":"2021","unstructured":"Matsuda Y, Mendelsohn BA. An overview of process development for antibody-drug conjugates produced by chemical conjugation technology. Expert Opin Biol Ther. 2021;21(7):963\u201375.","journal-title":"Expert Opin Biol Ther"},{"key":"3981_CR291","first-page":"81","volume":"15","author":"A Fukunaga","year":"2018","unstructured":"Fukunaga A, et al. Improvement of antibody affinity by introduction of basic amino acid residues into the framework region. Biochem Biophys Rep. 2018;15:81\u20135.","journal-title":"Biochem Biophys Rep"},{"issue":"4","key":"3981_CR292","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/14789450.2019.1578215","volume":"16","author":"A Beck","year":"2019","unstructured":"Beck A, et al. Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future. Expert Rev Proteomics. 2019;16(4):337\u201362.","journal-title":"Expert Rev Proteomics"},{"issue":"6","key":"3981_CR293","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","volume":"14","author":"R Chen","year":"2015","unstructured":"Chen R, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to Brentuximab Vedotin. Mol Cancer Ther. 2015;14(6):1376\u201384.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"3981_CR294","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.chembiol.2013.01.010","volume":"20","author":"P Strop","year":"2013","unstructured":"Strop P, et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 2013;20(2):161\u20137.","journal-title":"Chem Biol"},{"issue":"2","key":"3981_CR295","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.2108","volume":"30","author":"B-Q Shen","year":"2012","unstructured":"Shen B-Q, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30(2):184\u20139.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"3981_CR296","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","volume":"15","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers. 2023;15(3):713.","journal-title":"Cancers"},{"issue":"16","key":"3981_CR297","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/C8CS00676H","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh JD, et al. Cleavable linkers in antibody\u2013drug conjugates. Chem Soc Rev. 2019;48(16):4361\u201374.","journal-title":"Chem Soc Rev"},{"key":"3981_CR298","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1208\/s12248-014-9710-8","volume":"17","author":"JR McCombs","year":"2015","unstructured":"McCombs JR, Owen SC. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J. 2015;17:339\u201351.","journal-title":"AAPS J"},{"issue":"1","key":"3981_CR299","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","volume":"9","author":"K Tsuchikama","year":"2018","unstructured":"Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9(1):33\u201346.","journal-title":"Protein Cell"},{"issue":"4","key":"3981_CR300","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1021\/bc5005747","volume":"26","author":"M Dorywalska","year":"2015","unstructured":"Dorywalska M, et al. Effect of attachment site on stability of cleavable antibody drug conjugates. Bioconjug Chem. 2015;26(4):650\u20139.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"3981_CR301","first-page":"3","volume":"11","author":"M-R Nejadmoghaddam","year":"2019","unstructured":"Nejadmoghaddam M-R, et al. Antibody-drug conjugates: possibilities and challenges. Avicenna J Med Biotechnol. 2019;11(1):3.","journal-title":"Avicenna J Med Biotechnol"},{"issue":"8","key":"3981_CR302","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3390\/biomedicines9080872","volume":"9","author":"CM Mckertish","year":"2021","unstructured":"Mckertish CM, Kayser V. Advances and limitations of antibody drug conjugates for cancer. Biomedicines. 2021;9(8):872.","journal-title":"Biomedicines"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03981-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03981-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03981-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T23:02:51Z","timestamp":1767049371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03981-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":302,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3981"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03981-3","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2282"}}